Emelina Stambolliu | AI in Healthcare | Excellence in Research Award

Published on by AI Data Scientist

Dr. Emelina Stambolliu | AI in Healthcare | Excellence in Research Award

Supervising physician | Hippokration General Hopsital of Athens,Greece | Greece

Dr. Emelina Stambolliu is a clinician-researcher at Hippokration General Hospital of Athens whose work focuses on hypertension, kidney disease, and cardiovascular risk, with growing integration of AI-driven analysis in healthcare. Her research emphasizes advanced blood pressure monitoring (office, home, ambulatory), early detection of target-organ damage, and cardiorenal interactions across pediatric and adult populations. She has contributed extensively to evidence-based clinical decision support, systematic reviews, and validation of medical monitoring devices, supporting precision medicine and data-informed patient care


View Orcid Profile

Featured Publications

Ali Ghulam | AI in Healthcare | Best Researcher Award

Published on by AI Data Scientist

Dr. Ali Ghulam | AI in Healthcare | Best Researcher Award

Assistant Professor at Information Technology Centre, Sindh Agriculture University, Pakistan

Dr. Ghulam Ali is an accomplished academic and researcher specializing in artificial intelligence (AI) and bioinformatics. He earned his Ph.D. in Computer Software and Theory from Shaanxi Normal University, Xi’an, China, in 2020. Currently, he serves as an Assistant Professor at the Information Technology Centre, Sindh Agriculture University, Tandojam. His research focuses on human disease pathway network modeling, biological pathway database discovery, and AI-driven predictions related to proteins, drugs, and diseases. With over 20 published SCI articles in high-impact journals and extensive contributions to machine learning applications in bioinformatics, Dr. Ali is a recognized expert in his field.

Profile

Orcid

Education

Dr. Ali pursued his Ph.D. from Shaanxi Normal University, Xi’an, China, specializing in bioinformatics and AI. His thesis, titled “Prediction of Pathway Related Protein, Drug and Disease Association Based on Complex Network and Deep Learning,” was supervised by Prof. Xiujuan Lei. He completed his M.Phil. in Computer Science with a specialization in Search Engine Optimization from the University of Sindh, Jamshoro. His academic journey began with a Bachelor of Computer Science (BCS-Hons) from the same university. Additionally, he obtained various certifications and diplomas in information technology, further strengthening his expertise in computing and AI.

Experience

Dr. Ali has a strong academic and research background, currently holding the position of Assistant Professor at Sindh Agriculture University, Tandojam. His professional journey includes extensive work on bioinformatics, AI-based predictive models, and computational biology. He has contributed significantly to research in AI applications for human protein sequence analysis, disease detection, and biomedical data transformation. With a deep understanding of AI, deep learning, and machine learning techniques, he has played a pivotal role in advancing bioinformatics research and education.

Research Interests

Dr. Ali’s research primarily revolves around bioinformatics and artificial intelligence. He is particularly focused on human disease pathway modeling, drug-protein interaction prediction, and machine learning applications in genomics. His work involves utilizing AI to enhance precision diagnostics, early-stage disease detection, and advanced biomedical data analysis. By leveraging deep learning and AI-driven methodologies, Dr. Ali aims to improve healthcare analytics and disease treatment strategies. His research has practical implications in the fields of computational biology, digital health frameworks, and AI-driven medical solutions.

Awards and Recognitions

Dr. Ali has received numerous accolades for his contributions to AI and bioinformatics research. His high-impact factor publications and citations reflect his significant contributions to the scientific community. With an H-index of 12 on Google Scholar, an i10-index of 18, and a ResearchGate H-index of 11, his research has been widely recognized and cited. He has also been nominated for various research excellence awards, highlighting his influence in the field of computational biology and AI-driven biomedical advancements.

Publications

Ali, Ghulam, et al. (2025). “StackAHTPs: An explainable antihypertensive peptides identifier based on heterogeneous features and stacked learning approach.” IET Systems Biology, 19(1), e70002. (SCI, IF: 1.9, Cited by: X).

Arif, Muhammad, et al. (2024). “StackDPPred: Multiclass prediction of defensin peptides using stacked ensemble learning with optimized features.” Methods, 230, 129-139. (SCI, IF: 4.02, Cited by: X).

Arif, Muhammad, et al. (2024). “DPI_CDF: Druggable protein identifier using cascade deep forest.” BMC Bioinformatics, 25(1), 1-18. (SCI, IF: 3.09, Cited by: X).

Talpur, Fauzia, et al. (2024). “ML-Based Detection of DDoS Attacks Using Evolutionary Algorithms Optimization.” Sensors, 24(5), 1672. (SCI, IF: 3.09, Cited by: X).

Ghulam, Ali, et al. (2024). “Assessment of Performance of Machine Learning Classification Techniques for Monkey Pox Disease Detection.” Journal of Innovative Intelligent Computing and Emerging Technologies, 1(1), 1-7. (Cited by: X).

Memon, Mukhtiar, et al. (2023). “AiDHealth: An AI-enabled Digital Health Framework for Connected Health and Personal Health Monitoring.” (Cited by: X).

Sikander, Rahu, et al. (2023). “Identification of cancerlectin proteins using hyperparameter optimization in deep learning and DDE profiles.” Mehran University Research Journal of Engineering & Technology, 42(4), 28-40. (WoS, Cited by: X).

Conclusion

Dr. Ghulam Ali is a distinguished researcher and academician in the field of artificial intelligence and bioinformatics. His contributions to AI-driven biomedical research, particularly in disease pathway modeling and predictive analytics, have significantly advanced the field. With a strong publication record, multiple citations, and a commitment to innovation, he continues to influence computational biology and digital health research. His work bridges the gap between AI and medical sciences, paving the way for future breakthroughs in bioinformatics and AI-driven healthcare solutions.

Yuriy Gusev | AI in Healthcare | Best Use of Data in Healthcare Award

Published on by AI Data Scientist

Assoc. Prof. Dr. Yuriy Gusev | AI in Healthcare | Best Use of Data in Healthcare Award

Director of Health Informatics and Data Science Program at Georgetown University, United States

Yuriy Gusev is an esteemed Associate Professor of Bioinformatics at Georgetown University Medical Center’s Innovation Center for Biomedical Informatics (ICBI) and Department of Oncology. He is recognized for his extensive expertise in computational biology, bioinformatics, and systems biology, with a particular focus on cancer research. Dr. Gusev has dedicated his career to bioinformatics, computational modeling, and the development of innovative bioinformatics tools and methodologies. He also plays a leading role in the Health Informatics and Data Science graduate program, and co-directs the Biostatistics and Bioinformatics Shared Resource at the Lombardi Cancer Center. Throughout his career, Dr. Gusev has contributed significantly to multi-institutional cancer research efforts, particularly through large-scale studies, including the Georgetown Database of Cancer (G-DOC), and various NIH-funded programs.

Profile

Scopus

Education

Dr. Gusev’s academic journey began with a Master of Science in Applied Mathematics from State University of St. Petersburg in Russia. He later earned his Ph.D. in Computational Biology from the Central Research Institute of Roentgenology & Radiology in St. Petersburg, Russia. Dr. Gusev further honed his expertise with a postdoctoral position at the Waksman Institute, Rutgers University, where he focused on Computational Modeling in Cancer Research. These experiences laid the foundation for his innovative approach to bioinformatics and cancer research.

Experience

Dr. Gusev’s professional journey spans over three decades, with pivotal positions at several renowned institutions. After his postdoctoral work at Rutgers, he held various roles, including faculty research associate at Johns Hopkins University, senior research scientist at Molecular Staging Inc., and assistant professor at the University of Oklahoma Health Sciences Center. In 2009, he joined Georgetown University as an Associate Professor. Alongside his academic appointments, Dr. Gusev has directed numerous research projects and collaborated extensively in multi-disciplinary research programs across cancer genomics, bioinformatics, and computational biology.

Research Interests

Dr. Gusev’s research interests lie at the intersection of computational biology, bioinformatics, and cancer research. His primary focus includes the study of tumor heterogeneity, chromosomal instability, microRNA, and long-noncoding RNA regulation in cancer. He is particularly invested in the application of computational models and bioinformatics methods to analyze large-scale genomic and transcriptomic data. Dr. Gusev is also passionate about integrating molecular, imaging, and clinical data to advance personalized medicine and precision oncology. His work involves high-throughput data analysis, machine learning techniques for biomarker discovery, and the development of cloud-based platforms to streamline cancer research workflows.

Awards

Dr. Gusev has been recognized with numerous accolades throughout his career. Notable awards include the Charles and Johanna Bush Postdoctoral Fellowship, NSF travel awards for his work in tumor heterogeneity and mathematical population dynamics, and the Executive Leadership Award from the Mid-South Computational Biology and Bioinformatics Society. His contributions to computational cancer research were further acknowledged with the 2008 Executive Leadership Award, and his research impact continues to be recognized by various scientific bodies.

Publications

Dr. Gusev has authored or co-authored numerous influential publications. His research in tumor heterogeneity, chromosomal instability, and microRNA profiling has resulted in multiple highly cited papers. Some key publications include:

Axelrod DE, Gusev Y, Kuczek T. “Persistence of cell cycle times over many generations as determined by heritability of colony sizes of ras oncogene-transformed and non-transformed cells.” Cell Proliferation, 1993, 26(3), 235-249.

Gusev Y, Kagansky V, Dooley WC. “Long-term dynamics of chromosomal instability in cancer: a transition probability model.” Mathematical and Computer Modelling, 2001, 33(12), 1253-1273.

Gusev Y, Bhuvaneshwar K, Song L, Zenklusen JC, Fine H, Madhavan S. “The REMBRANDT study, a large collection of genomic data from brain cancer patients.” Nature Scientific Data, 2018; 5:180158.

Bhuvaneshwar K, Belouali A, Singh V, et al. “G-DOC Plus – an integrative bioinformatics platform for precision medicine.” BMC Bioinformatics, 2016; 17(1):193.

Lei Song, Krithika Bhuvaneshwar, Yue Wang, et al. “CINdex: a bioconductor package for analysis of chromosome instability in DNA copy number data.” Cancer Informatics, 2017, Volume 16, PMID: 29343938.

His works have been cited extensively, contributing to advances in cancer bioinformatics, precision oncology, and the study of molecular biomarkers in cancer.

Conclusion

Dr. Yuriy Gusev has made significant contributions to the field of computational biology and bioinformatics, particularly in cancer research. His work has greatly advanced the understanding of tumor heterogeneity, chromosomal instability, and non-coding RNA regulation in cancer. As an educator, researcher, and leader, he continues to influence the development of bioinformatics tools and platforms that facilitate precision medicine. Dr. Gusev’s expertise in computational modeling, genomic data analysis, and multi-omics integration positions him as a pivotal figure in cancer research and bioinformatics. His ongoing efforts to apply innovative computational approaches to clinical oncology will undoubtedly lead to further breakthroughs in cancer treatment and personalized therapies.